Field Moving Toward Genotype-Guided Psychotropic Therapy
SAN FRANCISCO, May 21 /PRNewswire/ -- Gualberto Ruano, M.D., Ph.D., President of Genomas, and Director of Genetics Research at Hartford Hospital and Simon Kung, M.D., Assistant Professor of Psychiatry at the Mayo Clinic will co-chair a symposium, "Emerging Clinical Applications of Genotype-Guided Psychotropics for Depressive Disorders," at the annual meeting of the American Psychiatric Association.
"Genotyping is at a point where it could be used to help guide therapeutic choices," said the Mayo Clinic's Dr. Kung. "It's fitting that Mayo Clinic, Genomas and Institute of Living/Hartford Hospital partnered on today's symposium since these institutions are among the true innovators in delivering personalized medicine to patients."
Papers presented at today's symposium were:
Greater Utilization of Psychiatric Services is Associated with Pharmacogenetic Variation and Metabolism Deficiencies
Gualberto Ruano, M.D., Ph.D., and John W. Goethe, M.D.
Genomas Inc. and Institute of Living/Hartford Hospital, Hartford, CT
Cytochrome P-450 2D6, 2C19, and Serotonin Transporter Genotyping for Depressed Inpatients at the Mayo Clinic Mood Disorders Unit
Simon Kung, M.D.
Mayo Clinic, Rochester, MN
Pharmacogenetic Testing in Psychiatry: Early Adopters' Attitudes and Practices
Jinger G. Hoop, M.D., M.F.A.
The Serotonin Transporter Gene (SLC6A4): Understanding Variability and Enhancing the Clinical Utility of Genotyping
David Mrazek, M.D.
Mayo Clinic, Rochester, MN
Dr. Ruano presented results from a study that showed a significant link between certain genetic variations and length of stay and re-hospitalization rates for patients treated for major depressive disorder (MDD). Data were obtained from the DNA of 150 psychiatric in-patients being treated for MDD with antidepressant and atypical antipsychotic medications at the Institute of Living.
"These genetic variations may contribute to a reduction in efficacy or an increase in side effects of medications," said Dr. Ruano.
Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company is developing and testing revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit www.genomas.net for more information.
Copyright©2009 PR Newswire.
All rights reserved